JP2014518069A - 骨髄異形成症候群対象の生存率を予測するための変異シグネチャー - Google Patents

骨髄異形成症候群対象の生存率を予測するための変異シグネチャー Download PDF

Info

Publication number
JP2014518069A
JP2014518069A JP2014516047A JP2014516047A JP2014518069A JP 2014518069 A JP2014518069 A JP 2014518069A JP 2014516047 A JP2014516047 A JP 2014516047A JP 2014516047 A JP2014516047 A JP 2014516047A JP 2014518069 A JP2014518069 A JP 2014518069A
Authority
JP
Japan
Prior art keywords
mutations
subject
mutation
mds
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014516047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518069A5 (enExample
Inventor
ラファエル ベジャー
ベンジャミン リバイン イバート
クリスティン スティーブンソン
ドナ ノイベルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2014518069A publication Critical patent/JP2014518069A/ja
Publication of JP2014518069A5 publication Critical patent/JP2014518069A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014516047A 2011-06-17 2012-06-15 骨髄異形成症候群対象の生存率を予測するための変異シグネチャー Pending JP2014518069A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498497P 2011-06-17 2011-06-17
US61/498,497 2011-06-17
PCT/US2012/042734 WO2012174419A2 (en) 2011-06-17 2012-06-15 Signatures for predicting the survivability of myelodysplastic syndrome subjects

Publications (2)

Publication Number Publication Date
JP2014518069A true JP2014518069A (ja) 2014-07-28
JP2014518069A5 JP2014518069A5 (enExample) 2015-07-30

Family

ID=46420545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516047A Pending JP2014518069A (ja) 2011-06-17 2012-06-15 骨髄異形成症候群対象の生存率を予測するための変異シグネチャー

Country Status (5)

Country Link
US (1) US10711308B2 (enExample)
EP (1) EP2721176A2 (enExample)
JP (1) JP2014518069A (enExample)
AU (1) AU2012271386A1 (enExample)
WO (1) WO2012174419A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528260A (ja) * 2016-08-03 2019-10-10 セルジーン コーポレイション 骨髄異形成症候群の治療方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2013018866A1 (ja) * 2011-08-02 2013-02-07 国立大学法人東京大学 骨髄異形成症候群または骨髄性腫瘍素因の評価方法、そのポリペプチド及び抗体、並びにその治療薬若しくは予防薬の候補物スクリーニング方法
WO2013151983A1 (en) * 2012-04-02 2013-10-10 The Cleveland Clinic Foundation Methods for predicting the prognosis of a subject with a myeloid malignancy
US11015223B2 (en) 2013-05-10 2021-05-25 The Regents Of The University Of California Methods for determining response to a hypomethylating agent
AU2014274276A1 (en) * 2013-05-31 2015-12-03 Onconova Therapeutics, Inc. Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disorders
US20160282354A1 (en) 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
JP2017533714A (ja) * 2014-11-12 2017-11-16 ネオゲノミクス ラボラトリーズ， インコーポレイテッド 末梢血血漿ｄｎａのディープシーケンシングは、骨髄異形成症候群の診断を確認するうえで信頼性が高い
EP3626832B1 (en) 2014-11-25 2024-06-12 The Brigham and Women's Hospital, Inc. Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease
WO2016085876A1 (en) * 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
EP3347712B1 (en) 2015-09-11 2022-05-11 The Broad Institute, Inc. Methods of identifying drug-modulated polypeptide targets for degradation
US11459613B2 (en) 2015-09-11 2022-10-04 The Brigham And Women's Hospital, Inc. Methods of characterizing resistance to modulators of Cereblon
EP3493809B1 (en) * 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
EP4520828A3 (en) * 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
KR101934107B1 (ko) * 2016-12-15 2018-12-31 가톨릭대학교산학협력단 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물
JP7416700B2 (ja) 2017-11-14 2024-01-17 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087702A1 (en) * 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5018067A (en) 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US20020038227A1 (en) 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
US7468032B2 (en) 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20040122296A1 (en) 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087702A1 (en) * 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528260A (ja) * 2016-08-03 2019-10-10 セルジーン コーポレイション 骨髄異形成症候群の治療方法
JP7093764B2 (ja) 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法

Also Published As

Publication number Publication date
EP2721176A2 (en) 2014-04-23
AU2012271386A1 (en) 2014-01-16
WO2012174419A3 (en) 2013-02-28
WO2012174419A2 (en) 2012-12-20
US20140127690A1 (en) 2014-05-08
US10711308B2 (en) 2020-07-14
WO2012174419A8 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
US10711308B2 (en) Mutation signatures for predicting the survivability of myelodysplastic syndrome subjects
US12221656B2 (en) Methods and materials for assessing homologous recombination deficiency
AU2014248007B2 (en) Methods and materials for assessing homologous recombination deficiency
JP2015512630A (ja) 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物
JP7197915B2 (ja) エンザスタウリンの活性を予測するための方法および組成物
US20160024591A1 (en) Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
US20150218637A1 (en) Genetic markers for predicting responsiveness to fgf-18 compound
AU2013301607A1 (en) Prognosis biomarkers in cartilage disorders
WO2017112738A1 (en) Methods for measuring microsatellite instability
CA2657493A1 (en) Prognostic method
US11015223B2 (en) Methods for determining response to a hypomethylating agent
WO2017165270A1 (en) Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer
US20220205043A1 (en) Detecting cancer risk
WO2017106365A1 (en) Methods for measuring mutation load
US20220017967A1 (en) Molecular signature
US20230212653A1 (en) Methods and materials for assessing homologous recombination deficiency in breast cancer subtypes
Haja Mohideen Analysis of variations in hypoxia-pathway genes and mitochondrial DNA as prognostic markers in colorectal cancer patients
NZ712663B2 (en) Methods and materials for assessing homologous recombination deficiency

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170816